Moolec Science Sa · NASDAQ:MLEC
Moolec Science Sa — Q4 FY2024 Earnings Presentation
14 slides from Moolec Science Sa's earnings presentation, Oct 7, 2024
Slide 1: Exhibit 99.2
Exhibit 99.2
Slide 2: 4th Quarter Fiscal Year 2024 Business Update
4th Quarter Fiscal Year 2024 Business. Update
Slide 3: Slide 3
Slide 4: Moolec Science Presents Fiscal Year 2024 Annual Business Update
Moolec Science Presents Fiscal Year 2024 Annual Business Update Luxembourg. October 2, 2024 – Moolec Science SA (NASDAQ: MLEC; “The Company”; “Moolec”) a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today reported its Business Update for
Slide 5: Conference Call
Conference Call Management will host a Conference Call and question-and-answer session, which will be accompanied by a presentation available during the webinar. To access the call, please use the following information: ● Date: Wednesday, October 2, 2024 ● Time: 08:30 AM Eastern Time (US and Canada)
Slide 6: About Moolec Science SA
About Moolec Science SA Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food and dietary supplementation markets. The Company’s mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine
Slide 7: Scientific and Operational Progress: GLASO Safflower Platform
1. Scientific and Operational Progress a. GLASO™ | Safflower Platform GLASO™ (gamma-linolenic acid -GLA- in safflower oil) will be Moolec Science’s first Molecular Farming product to hit the market. Moolec’s GLASO™ contains almost 3 times more GLA than conventional sources such as borage and primros
Slide 8: Piggy Sooy Soybean Platform
b. Piggy Sooy™| Soybean Platform Piggy Sooy™ is Moolec Science’s patented soybean platform engineered to produce high levels of porcine myoglobin in soybean seeds. Expression levels reached over 20% of total soluble protein in T2 stage and maintained high levels in T3 stage, setting new benchmarks i
Slide 9: What to expect in FY 2025: Product Pipeline
2. What to expect in FY 2025 a. Product Pipeline ● GLASO™: A counter season is expected to be carried out in the Southern Hemisphere for seed increase and seed preparation for a larger- scale GLASO™ grain production campaign and subsequent crush processing. Additionally, we will continue to develop
Slide 10: Financial overview: Review of consolidated results FY 2024 vs FY 2023
3. Financial overview Review of consolidated results FY 2024 vs FY 2023 Company reported figures are presented applying IAS 29 accounting for its Argentinean subsidiary. The following table shows “As reported” in conjunction with “Excluding IAS 29” results in order to provide more context for the ev
Slide 11: Statement of Financial Position
b) Statement of Financial Position ● As of June 30, 2024, there was an increase of $10,735.7 thousand or 45% in our total assets arising to $34,786.9 thousand compared to FY2023. ● Current assets, which mainly comprise cash and cash equivalents, inventories and trade receivables increased by $8,416.
Slide 12: ANNEX: Statement of Operations, Financial Position and Cash Flow Statement
ANNEX: Statement of Operations, Statement of Financial Position and Cash Flow Statement Consolidated statements of operations For the For the For the For the three months three months fiscal year fiscal year ended ended ended ended June 30, June 30, June 30, June 30, 2024 2023 Change 2024 2023 Chang
Slide 13: Condensed consolidated statements of financial position
Condensed consolidated statements of financial position As of As of June 30, June 30, 2024 2023 Change (In thousands of U.S. dollars, unless otherwise noted) (%) Current assets 13,748.4 5,331.8 158% Non-current assets 21,038.5 18,719.4 12% Total assets 34,786.9 24,051.2 45% Equity 6,815.7 10,106.0 (
Slide 14: Condensed consolidated statements of cash flows
Condensed consolidated statements of cash flows For the For the fiscal year fiscal year ended ended June 30, June 30, 2024 2023 Change (In thousands of U.S. dollars, unless otherwise noted) (%) Net cash (used) / generated in operating activities (9,328.3) (7,511.4) 24% Net cash (used) / generated fr